Diagnostic work‐up of acute myeloid leukemia
- 3 February 2017
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 92 (3) , 317-321
Abstract
Acute myeloid leukemia (AML) is characterized by a clonal expansion of undifferentiated myeloid precursors resulting in impaired hematopoiesis and bone marrow failure. In 2016, the World Health Organization (WHO) published revisions to the classification of myeloid neoplasms and acute leukemias. Similar to the 2008 classification, the updated classification incorporates clinical features, morphology, immunophenotyping, and cytogenetics, with greater emphasis on molecular genetics, to define disease entities. This brief review addresses the various components of pathologic assessment to establish a diagnosis of AML and to help risk stratify patients, with an emphasis on newer techniques used in the detection of mutations with prognostic significance, as well as assays employed in the evaluation of minimal residual disease following treatment.Keywords
This publication has 18 references indexed in Scilit:
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesBlood, 2015
- Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemiaLaboratory Investigation, 2015
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Hematology-American Society Hematology Education Program, 2014
- Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant diseaseLeukemia, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate‐risk acute myeloid leukemiaCytometry Part B: Clinical Cytometry, 2012
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeNew England Journal of Medicine, 2009
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid LeukemiaNew England Journal of Medicine, 2008
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002